Currently, no data are available on the burden of morbidity and mortality in people with HIV-1 (PWH) harboring a 4-class drug-resistant (4DR) virus (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors). The study aimed to assess the incidence of clinical events and death in this population.
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry / Galli, L., Parisi, M.R., Poli, A., Menozzi, M., Fiscon, M., Garlassi, E., Francisci, D., Di Biagio, A., Sterrantino, G., Fornabaio, C., Degli Antoni, A., Angarano, G., Fusco, F.M., D'Arminio Monforte, A., Corbelli, G.M., Santoro, M.M., Zazzi, M., Castagna, A.. - In: OPEN FORUM INFECTIOUS DISEASES. - ISSN 2328-8957. - 7:11(2020), p. ofaa456. [10.1093/ofid/ofaa456]
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry
Castagna, AntonellaUltimo
2020-01-01
Abstract
Currently, no data are available on the burden of morbidity and mortality in people with HIV-1 (PWH) harboring a 4-class drug-resistant (4DR) virus (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors). The study aimed to assess the incidence of clinical events and death in this population.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
